Study Finds CellerateRX Powder Saves $3,852 Per Patient in Spine Surgery
A peer-reviewed study in the Journal of Medical Economics found adding CellerateRX Surgical Powder to standard care for high-risk spinal surgery patients saved $3,852 per patient and delivered a 0.007 QALY gain, yielding a $4,542 net monetary benefit. Avoided hospital readmissions and surgical revisions accounted for $3,073 of the savings.
1. Published Peer-Reviewed Study
Sanara’s CellerateRX Surgical Powder underwent economic and clinical evaluation in the Journal of Medical Economics, modeling outcomes for high-comorbidity spinal surgery patients. Researchers compared adjunctive CellerateRX treatment with standard of care over a one-year horizon, measuring postoperative complications, readmissions, reoperations, QALYs and direct medical costs in 2025 dollars.
2. Significant Cost-Effectiveness Results
The CellerateRX arm delivered $3,852 in cost savings and a 0.007 QALY gain per patient, translating to a $4,542 net monetary benefit. Avoidance of hospital readmissions and surgical revisions accounted for $2,238 and $835 of savings, and the treatment arm showed dominant cost-effectiveness in over 99% of simulations.
3. Strategic Implications for Sanara MedTech
These findings strengthen CellerateRX’s value proposition by demonstrating both clinical and economic benefits in spine surgery markets. Strong cost-effectiveness evidence may accelerate hospital adoption, support reimbursement negotiations and enhance Sanara’s position in the North American surgical tissue repair market.